Drug Trial Radar · NCT06408727
Intermediate Expanded Access Protocol CNMAu8.EAP04
Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Temporarily not available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Clene NanomedicineIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- May 10, 2024
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
Conditions
- ALS
- Amyotrophic Lateral Sclerosis
- PALS
Interventions
CNM-Au8Drug
CNM-Au8 (cellular energetic nanocatalyst). Faceted clean-surfaced catalytically-active Au nanocrystals.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Nova Southeastern University
Fort Lauderdale, Florida
Northwestern University
Chicago, Illinois
Synapticure
Chicago, Illinois
University of Iowa
Iowa City, Iowa
Columbia Unniversity
New York, New York
Duke University
Durham, North Carolina
Pennsylvania State University
Hershey, Pennsylvania
Texas Neurology
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.